Clinical trial NCT06377111: A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
Official title: Phase 1 Trial of PANtoTHEnic Acid in Patient With Metastatic or Unresectable Melanoma ON ImmunOtherapy (PANTHEON-IO)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Melanoma (Skin)
Keywords: Vitamin B5
Unresectable melanoma
Metastatic melanoma
Pantothenic acid
Combined immune checkpoint inhibitors
ICI
Nivolumab
Ipilimumab
Anti-PD-1 antibody
Anti-CLTA-4 antibody
Skin cancer
Melanoma
Calcium pantothenate
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2024-04-22
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is open to patients with a type of cancer called melanoma. Patients can join the study if their tumor cannot be removed by surgery or has spread to other organs, and are planned to receive immunotherapy as treatment for their cancer. This study is looking at whether taking calcium pantothenate supplement (a type of Vitamin B5) can increase its levels in the blood and have an effect in the immune system, when its used in combination with the immunotherapy.

Detailed description: This single-center, single-cohort study aims to investigate the effectiveness of oral calcium pantothenate (C-PAN) in raising plasma pantothenic acid levels in melanoma patients. Conducted at Princess Margaret Cancer Centre, the study will enroll 12 eligible subjects with locally unresectable or metastatic melanoma undergoing first-line standard of care (SOC) with combined immune checkpoint inhibitor (ICI) therapy, Nivolumab and Ipilimumab. Additionally, the study will explore changes in immune cell subsets, metabolomics, and gut microbiome to understand the impact of pantothenate/CoA pathway manipulation on ICI efficacy and immune-mediated colitis prevention.

Patients will initially receive a run-in period of C-PAN at a dose of 2000 mg daily for 3 to 7 days, alongside approved SOC drugs. Subsequently, patients will continue with the maintenance dose of 2000 mg daily, starting on the same day as the first cycle of combined ICI. This maintenance dose will be continued until the occurrence of unacceptable toxicity, disease progression by iRECIST criteria, or for a maximum duration of 1 year, whichever comes first, unless there are specific criteria indicating the discontinuation of C-PAN.

For all subjects, radiologic imaging to assess response to treatment will be performed as per standard practice (ideally every 8 to 12 weeks, with first assessment at week 9). Fecal samples will be collected from all subjects at baseline (1st sample), at week 9 following the start of ICI, and at study completion or discontinuation. An additional fecal sample will be collected in case of development of immune-related colitis or immune-related diarrhea.

Standard laboratory investigations for immunotherapy will be collected as per institutional practice. Blood samples for biomarkers will be collected at various time points.

Eligibility criteria: Inclusion Criteria:

* 1. Signed written and voluntary informed consent.
* 2. Age ≥18 years, male or female.
* 3. Have histologically or cytological documented unresectable stage III or stage IV metastatic melanoma (AJCC 8th edition).
* 4. Have not received any previous systemic treatment for advanced melanoma, including chemotherapy, immunotherapy or targeted therapy.
* 5. Be willing and able to provide stool and blood specimen for analyses at protocol specified time points.
* 6. Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
* 7. Not pregnant for females of child bearing potential as indicated by negative serum or urine pregnancy test within 72 hours of study start

Exclusion Criteria:

* 1. Subjects unable to swallow orally administered medications or any subjects with gastrointestinal disorders likely to interfere with absorption (e.g. bowel obstruction, short gut syndrome, blind loop syndrome, ileostomy, etc.). Subjects with colostomies may be enrolled.
* 2. Subjects with inflammatory bowel disease.
* 3. Any condition that, in the opinion of the Investigator, would interfere with subject safety, or evaluation of the collected specimen and interpretation of study result.
* 4. Pregnant or planning to get pregnant in the next 6 months.
* 5. Female patient breastfeeding.
* 6. Allergy to the investigational product (or its non-medicinal ingredients)- Calcium Pantothenate (stearic acid, Hydroxypropyl methylcellulose) or Immune checkpoint inhibitors (or its non-medicinal ingredients)- Nivolumab (Hydrochloric acid, mannitol (E421), pentetic acid, polysorbate 80, sodium chloride, sodium citrate, sodium hydroxide) and Ipilimumab (diethylene triamine pentaacetic acid (DTPA), mannitol, polysorbate 80, sodium chloride, Tris-hydrochloride, sodium hydroxide, hydrochloric acid

Primary outcomes:
measure: To determine if the dose of 2000 mg daily of pantothenic acid achieves an increase in plasmatic concentration of pantothenic acid by at least a 50% between baseline and week 9, in 9 or more of the patients treated with combined ICI.
timeFrame: 9 weeks
Secondary outcomes:
measure: Evaluate the overall response rate (ORR) of the enrolled cohort.
timeFrame: 1 year
measure: Evaluate the progression free survival (PFS) of the enrolled cohort.
timeFrame: 1 year
measure: Incidence of immune-related colitis.
timeFrame: 1 year
measure: Correlation between baseline intestinal microbiome composition to the development of immune-related colitis.
timeFrame: 1 year
measure: Correlation between the early changes in composition of intestinal microbiome and the development of immune-related colitis.
timeFrame: 1 year
measure: The incidence of treatment-related adverse events.
timeFrame: 1 year
measure: The incidence of treatment-related adverse events
timeFrame: 1 year
measure: Correlation between change in plasmatic pantothenic acid level between baseline and at first day of ICI, and ORR.
timeFrame: 1 year
Other outcomes:
measure: Correlation between change in pantothenic acid plasmatic level in mcMol/L between baseline and first day of ICI, and ORR by RECIST and iRECIST.
timeFrame: 2 weeks
measure: Correlation between change in plasmatic pantothenic acid level between baseline and week 9 assessment, and immune profiling.
timeFrame: 9 weeks
Locations:
city: Toronto
country: Canada
facility: University Health Network- Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: The Princess Margaret Cancer Foundation
name: Samuel Saibil
role: PRINCIPAL_INVESTIGATOR
References: